FDA Approves Activin Signaling Inhibitor for Bone Disorder

FDA Approves Activin Signaling Inhibitor for Bone Disorder

(MedPage Today) -- The FDA approved garetosmab (Pasatru) to reduce the formation of new heterotopic ossification lesions and disease flares in adults with fibrodysplasia ossificans progressiva (FOP), the agency announced on Wednesday. A monoclonal...

US FDA approves Regeneron’s rare bone disorder drug

Aug 19 - The U.S. FDA on Wednesday approved Regeneron's experimental drug for a rare ​genetic disorder after it ‌significantly reduced abnormal bone formation in certain soft tissues. The New York-based Regeneron's shares rose 4%. The drug, garetosmab,...

Regeneron rare bone disorder therapy approved (REGN:NASDAQ)

Regeneron (REGN) stock gains as the FDA OKs the company's antibody drug, Pasatru, for a rare bone disorder called fibrodysplasia ossificans progressiva. Read more here.

Regeneron drug for disease that causes dangerous bone growth earns FDA approval

Patients with FOP form bone where it shouldn't be. The drug, Pasatru, drastically cut the risk of new bone growth in a trial.

FDA Approves Regeneron’s Pasatru for Fibrodysplasia Ossificans Progressiva, Expanding Treatment Options

As reported on BioSpace, the U.S. Food and Drug Administration has approved Regeneron’s Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder that causes bone to form in muscles, tendons, ligaments, and other soft tissues. The approval gives patients a second FDA-approved treatment option and introduces new competition in a market […]